<DOC>
	<DOCNO>NCT00509379</DOCNO>
	<brief_summary>The promising activity Bortezomib single agent low grade lymphoma patient small study lead number large multicenter trial Bortezomib combination Rituximab mantle-cell lymphoma , follicular lymphoma marginal zone lymphoma .</brief_summary>
	<brief_title>Non-randomized Safety Study With Bortezomib/Rituximab Relapsed/Refractory Indolent Lymphoma</brief_title>
	<detailed_description>This open label , non randomize , phase II , multicenter , prospective trial evaluate efficacy safety combination bortezomib rituximab patient relapse refractory rituximab na誰ve sensitive indolent non-follicular mantle cell non-Hodgkin 's lymphoma . Despite availability treatment disease , study justify know therapy really curative necessary look new treatment option improve clinical outcome prognosis relapse indolent lymphoma . This study design patient eligible high-dose chemotherapy autologous stem cell transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Patients na誰ve sensitive rituximab indolent nonfollicular mantle cell nonHodgkin 's Lymphoma disease fail respond relapse primary therapy . There demonstrated progressive disease require treatment . Histological subtype include study follow Small lymphocytic/lymphoplasmocytic lymphoma ; Nodal marginal zone Lymphoma ( MALT lymphoma exclude ) Splenic marginal zone lymphoma Mantle cell lymphoma A lymphnode biopsy advisable harmful patient , enrollment patient study order confirm diagnosis rule histologic transformation . Lymphnode biopsy perform within 6 month study entry . 2 . Age &gt; 1875 3 . Relapse failure respond one ( maximum three ) line chemotherapy 4 . Any type prior chemotherapy , rituximab include . Patients receive high dose chemotherapy ASCT enrol study 5 . Na誰ve sensitive rituximab disease . If patient receive Rituximab , he/she must respond TTP last dose rituximab must 6 month . 6 . Measurable and/or evaluable disease . 7 . Adequate haematological count : ANC &gt; 1.0 x 109/L PLT count &gt; 75 x 109/L unless due bone marrow involvement lymphoma . 8 . Conjugated bilirubin 2 x ULN . 9 . Alkaline phosphatase transaminases 2 x ULN . 10 . Creatinine clearances &gt; 30 m/min . 11 . Non peripheral neuropathy CNS disease . 12 . Life expectancy &gt; 6 month . 13 . Performance status &lt; 2 accord ECOG scale . 14 . Written inform Consent 1 . Has know suspect hypersensitivity intolerance rituximab , boron , mannitol , heparin , indwell catheter use 2 . History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance 3 . Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug 4 . Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 5 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 5 . History hypotension decrease blood pressure ( sit systolic blood pressure SBP 100 mmHg and/or sit diastolic blood pressure DBP 60 mmHg ) 6 . Pregnant breastfeed 7 . Peripheral Neuropathy Neuropathic Pain Grade 2 8 . HIV positivity 9 . HBV positivity exception patient HBVcAb + , HbsAg , HBs Ab+/ HBVDNA negative 10 . HCV positivity exception patient sign active chronic hepatitis histologically confirm 11 . Active opportunistic infection 12 . Receipt extensive radiation therapy , systemic chemotherapy , antineoplastic therapy within 4 week enrollment 13 . Exposure Rituximab within 24 week screen 14 . Have receive experimental drug use experimental medical device within 4 week plan start treatment . Concurrent participation nontreatment study allow , interfere participation study . 15 . Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Relapsed/refractory indolent lymphoma</keyword>
	<keyword>Non-follicular Lymphoma</keyword>
	<keyword>Mantle cell non-Hodgkin Lymphoma</keyword>
	<keyword>Patients na誰ve sensitive rituximab</keyword>
	<keyword>Patients eligible high dose chemotherapy ASCT</keyword>
</DOC>